Phosphatidylcholine Biosynthesis as a Target for Phospholipid Analogues
In current anticancer therapies, most cytostatic agents impair cell division by crosslinking DNA (e.g. cis-platin or alkylating agents), disrupting the cytoskeleton (e.g. vinblastine) or rectifying the cytoskeleton (e.g. taxol). In a new approach to cancer chemotherapy, the cell membrane was described as a target for cytostatic agents. It is known that alkyl-lysophospholipids possess antineoplastic properties in vitro and in vivo1, leading to the development of an other class of antiproliferative phospholipid analogues, the alkylphosphocholines. One of these phospholipid analogues, hexadecylphosphocholine (HePC), has been shown to inhibit cell proliferation and tumour growth 2–4.
KeywordsHaCaT Cell Choline Chloride Cytostatic Agent German Cancer Research Mock Cell
Unable to display preview. Download preview PDF.
- 1.Berdel, W. E., Andreesen, R., and Munder, P.G. (1985) in Phospholipids and cellular Regulation Kuo, J. F. et. al. Vol. 2, pp. 41–73, CRC Press, Boca Raton, FL.Google Scholar
- 11.Wieder, Th., Perlitz, C., Wieprecht, M., Huang, R.T.C., Geilen, C.C., ans Orfanos, C.E. (1995) Biochem. J., in press.Google Scholar